Single-cell high-dimensional imaging mass cytometry: one step beyond in oncology

Abstract

Solid tumors have a dynamic ecosystem in which malignant and non-malignant (endothelial, stromal, and immune) cell types constantly interact. Importantly, the abundance, localization, and functional orientation of each cell component within the tumor microenvironment vary significantly over time and in response to treatment. Such intratumoral heterogeneity influences the tumor course and its sensitivity to treatments. Recently, high-dimensional imaging mass cytometry (IMC) has been developed to explore the tumor ecosystem at the single-cell level. In the last years, several studies demonstrated that IMC is a powerful tool to decipher the tumor complexity. In this review, we summarize the potential of this technology and how it may be useful for cancer research (from preclinical to clinical studies).

Development of a high dimensional imaging mass cytometry panel to investigate spatial organization of tissue microenvironment in formalin-fixed archival clinical tissues

“…ABs against VE-cadherin (E6N7A), Arginase-1 (D4E3M, Abcam) and PD-1 (EPR4877) did not work after metal conjugation. This could be explained by the fact that conformational changes or destruction of antigen binding sites during metal conjugation step might have occurred [ 40 ]. Lastly, pre-conjugated ABs purchased from supplier were validated on cTMA cores, even though they were pathologist verified.…”

Development of a high dimensional imaging mass cytometry panel to investigate spatial organization of tissue microenvironment in formalin-fixed archival clinical tissues

“…ABs against VE-cadherin (E6N7A), Arginase-1 (D4E3M, Abcam) and PD-1 (EPR4877) did not work after metal conjugation. This could be explained by the fact that conformational changes or destruction of antigen binding sites during metal conjugation step might have occurred [27]. Lastly, pre-conjugated ABs purchased from supplier, even though pathologist verified needs to be validated again.…”

Harnessing the n+1 dimensions of single-cell omics data for the prediction and prevention of human diseases

“…Dyani Gaudilliere 1 • Brice Gaudilliere 2 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023…”

“…This issue further explores how single-cell technologies, particularly those that afford spatial resolution, are currently implemented in clinical outcome studies for the discovery of predictive biomarkers, novel pathobiological mechanisms, or therapeutic targets. Drawing from examples across multiple technologies, such as single-cell RNA sequencing (scR-NAseq), spatial transcriptomics, COdetection by indexing (CODEX), and suspension and imaging mass cytometry (IMC), and diseases (from infectious and neurovascular diseases to transplantation and cancer), all authors contributing to this special issue emphasize important considerations with respect to clinical study design, sample processing, and the choice of machine learning-based analytical pipelines [1][2][3][4][5][6][7][8][9][10].…”

“…Several articles of this special issue focus on application of spatial proteomics and transcriptomics technologies to study the tumor immune microenvironment. In their review, Glasson et al shed light on how spatial omics can be leveraged to characterize dynamically the cellular ecosystem of solid tumors over time and over the course of treatment [2]. Wlosik et al discuss future prospect for high-content suspension and tissue-based omics approaches to address the need for predictive biomarkers of non-small cell lung cancer (NSCLC) clinical outcomes [3].…”